Lexicon Pharmaceuticals, Inc.
LXRX
$1.62
$0.010.62%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.49M | 14.18M | 28.87M | 1.26M | 26.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.49M | 14.18M | 28.87M | 1.26M | 26.55M |
| Cost of Revenue | -43.32M | 18.77M | 1.65M | 1.60M | -51.61M |
| Gross Profit | 48.81M | -4.59M | 27.21M | -342.00K | 78.16M |
| SG&A Expenses | 8.76M | 7.60M | 9.35M | 11.61M | 32.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.27M | 26.37M | 25.13M | 26.94M | 58.19M |
| Operating Income | -14.78M | -12.19M | 3.74M | -25.68M | -31.64M |
| Income Before Tax | -15.53M | -12.77M | 3.25M | -25.30M | -33.77M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.53M | -12.77M | 3.25M | -25.30M | -33.77M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.53M | -12.77M | 3.25M | -25.30M | -33.77M |
| EBIT | -14.78M | -12.19M | 3.74M | -25.68M | -31.64M |
| EBITDA | -14.66M | -12.04M | 3.91M | -25.50M | -31.51M |
| EPS Basic | -0.04 | -0.04 | 0.01 | -0.07 | -0.09 |
| Normalized Basic EPS | -0.03 | -0.02 | 0.01 | -0.04 | -0.06 |
| EPS Diluted | -0.04 | -0.04 | 0.01 | -0.07 | -0.09 |
| Normalized Diluted EPS | -0.03 | -0.02 | 0.01 | -0.04 | -0.06 |
| Average Basic Shares Outstanding | 363.43M | 363.40M | 363.29M | 362.07M | 361.49M |
| Average Diluted Shares Outstanding | 363.43M | 363.40M | 363.57M | 362.07M | 361.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |